SCHEMBL23624272

SCHEMBL23624272

CCCN(CCN1CCOCC1)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSPO P30536 4/20 0.77
▸ NR1I2 O75469 1/20 0.77
▸ ABCB11 O95342 1/20 0.77
▸ ALB P02768 1/20 0.77
▸ ADORA3 P0DMS8 1/20 0.77
▸ ADORA1 P30542 1/20 0.77
▸ OPRM1 P35372 1/20 0.77
▸ DRD3 P35462 1/20 0.77
▸ OPRK1 P41145 1/20 0.77
▸ PDE4D Q08499 1/20 0.77
▸ KCNH2 Q12809 1/20 0.77
▸ GABRA2 P47869 1/20 0.69
▸ GABRB2 P47870 1/20 0.69
▸ SLC2A1 P11166 4/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ HTT P42858 1/20 0.59
▸ GMNN O75496 1/20 0.58
▸ LMNA P02545 1/20 0.58
▸ POLB P06746 1/20 0.58
▸ CYP3A4 P08684 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23624214 0.92 TSPO (0.81) TSPONR1I2ABCB11ALBADORA3
SCHEMBL23624259 0.91 TSPO (0.80) TSPONR1I2ABCB11ALBADORA3
SCHEMBL23624291 0.89 TSPO (0.60) TSPONR1I2ABCB11ALBADORA3
SCHEMBL23624227 0.88 SLC2A1 (0.62) TSPONR1I2ABCB11ALBADORA3
Alpidem SCHEMBL122619 0.88 TSPO (1.00) TSPONR1I2ABCB11ALBADORA3
SCHEMBL19444411 0.84 TSPO (0.92) TSPONR1I2ABCB11ALBADORA3
SCHEMBL23624269 0.82 TSPO (0.88) TSPONR1I2ABCB11ALBADORA3
SCHEMBL6642731 0.82 TSPO (0.88) TSPONR1I2ABCB11ALBADORA3
SCHEMBL23624329 0.82 TSPO (0.83) TSPONR1I2ABCB11ALBADORA3
SCHEMBL23624249 0.82 TSPO (0.86) TSPONR1I2ABCB11ALBADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230051850-A1 COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-02-16 — — US disclosed
US-20210206771-A1 COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-07-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230051850-A1 COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT PMP22, GABBR1, MECP2 TSPO 275/4885NR1I2 2107/4885ABCB11 4085/4885
US-20210206771-A1 COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT PMP22, GABBR1, MECP2 TSPO 275/4885NR1I2 2107/4885ABCB11 4085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback